Br J Haematol . Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant

[tetano]

Br J Haematol


. 2021 Oct 20.
doi: 10.1111/bjh.17911. Online ahead of print.
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant


Amandine Le Bourgeois[SUP] 1 [/SUP], Marianne Coste-Burel[SUP] 2 [/SUP], Thierry Guillaume[SUP] 3 [/SUP], Pierre Peterlin[SUP] 1 [/SUP], Alice Garnier[SUP] 1 [/SUP], Berthe-Marie Imbert[SUP] 2 [/SUP], Thomas Drumel[SUP] 2 [/SUP], Beatrice Mahé[SUP] 1 [/SUP], Viviane Dubruille[SUP] 1 [/SUP], Nicolas Blin[SUP] 1 [/SUP], Anne Lok[SUP] 1 [/SUP], Cyrille Touzeau[SUP] 1 [/SUP], Thomas Gastinne[SUP] 1 [/SUP], Benoît Tessoulin[SUP] 1 [/SUP], Maxime Jullien[SUP] 1 [/SUP], Sophie Vantyghem[SUP] 1 [/SUP], Philippe Moreau[SUP] 1 [/SUP], Steven Le Gouill[SUP] 1 [/SUP], Marie C Béné[SUP] 3 4 [/SUP], Patrice Chevallier[SUP] 1 3 [/SUP]



Affiliations

• PMID: 34671982
• DOI: 10.1111/bjh.17911

No abstract availableKeywords: BNT162b2; allogeneic haematopoietic stem cell transplantation; coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA; third dose; vaccine.